Stand‐alone intrathecal central nervous system (CNS) prophylaxis provide unclear benefit in reducing CNS relapse risk in elderly DLBCL patients treated with R‐CHOP and is associated increased infection‐related toxicity-Reference-Cited by-同舟云学术

Stand‐alone intrathecal central nervous system (CNS) prophylaxis provide unclear benefit in reducing CNS relapse risk in elderly DLBCL patients treated with R‐CHOP and is associated increased infection‐related toxicity

Published:2019-06-20 Issue:2 Volume:187 Page:185-194
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Eyre Toby A.¹^ORCID,Kirkwood Amy A.²,Wolf Julia³,Hildyard Catherine⁴,Mercer Carolyn¹,Plaschkes Hannah⁵,Griffith John³,Fields Paul⁶,Gunawan Arief⁶,Oliver Rebecca⁷,Booth Stephen⁸,Martinez‐Calle Nicolas⁹,McMillan Andrew⁹,Bishton Mark⁹^ORCID,Fox Christopher P.⁹,Collins Graham P.¹,Hatton Chris S. R.¹

Affiliation:

1. Department of Haematology Churchill Hospital, Oxford University Hospitals NHS Foundation Trust Oxford UK

2. Cancer Research UK & UCL Cancer Trials Centre UCL Cancer Institute, UCL London UK

3. Department of Haematology Great Western Hospital Swindon UK

4. Department of Haematology Milton Keynes Hospital Oxford UK

5. Oxford University Medical School Oxford UK

6. Department of Haematology Guys and St Thomas’ Hospitals NHS Foundation Trust London UK

7. Department of Haematology University Hospitals Bristol NHS Foundation Trust Bristol UK

8. Department of Haematology Royal Berkshire Hospital NHS Foundation Trust Reading UK

9. Department of Clinical Haematology Nottingham University Hospitals NHS Trust Nottingham UK

Funder

National Institute for Health Research

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.16070

Reference25 articles.

1. Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma

2. CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)

3. Central nervous system relapse in patients over 80 years with diffuse large B-cell lymphoma: an analysis of two LYSA studies

4. A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma

5. Randomized Trial Comparing R-CHOP Versus High-Dose Sequential Chemotherapy in High-Risk Patients With Diffuse Large B-Cell Lymphomas

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identification, risk factors, and clinical course of CNS relapse in DLBCL patients across 19 prospective phase 2 and 3 trials—a LYSA and GLA/ DSHNHL collaboration;Leukemia;2024-08-16

2. Central nervous system prophylaxis in large B‐cell lymphoma: A British Society for Haematology Good Practice Paper;British Journal of Haematology;2024-08-11

3. Central Nervous System Prophylaxis Utilization in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Within a Large Community Health System;Journal of Patient-Centered Research and Reviews;2024-07-16

4. Clinical implications of CSF-ctDNA positivity in newly diagnosed diffuse large B cell lymphoma;Leukemia;2024-05-15

5. IELSG30 phase 2 trial: intravenous and intrathecal CNS prophylaxis in primary testicular diffuse large B-cell lymphoma;Blood Advances;2024-03-18